Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: A retrospective study

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 4125-4130

  Lorgis, Veronique ^a   Chauffert, Bruno ^b   Gentil, Julie ^a   Ghiringhelli, François ^a,c,d  

^a Georges Francois Leclerc Cancer Center   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d Institut Médical de Génétique et d Immunologie   (France)

Author keywords

5 Fluorouracil; FOLFIRINOX; Irinotecan; Lencovorin; Metastatic pancreatic adenocarcinoma; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; METASTATIC PANCREATIC ADENOCARCINOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LOCALIZATION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CASE-CONTROL STUDIES; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866990918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics,. CA Cancer J Clin 53: 5-26, 2003.
2. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, EUROCARE Working Group: EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 14: 61-118, 2003.
3. Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol 29: 23-31, 2002.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
5. Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 29: 31-39, 2002.
6. Bayraktar S, Bayraktar UD and Rocha-Lima CM: Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.World J Gastroenterol 16: 673-682, 2010.
7. Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB and Taieb J: Medical treatment of pancreatic cancer: New hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 35: 364-374, 2011.
8. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
9. Ko AH: FOLFIRINOX: A small step or a great leap forward? J Clin Oncol 29: 3727-3729, 2011.
10. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul J-L, Cattan S, Phelip J-M, Hammel P, Chauffert B, Michel P, Legoux J-L, Rougier P, Bedenne L and Seitz J-F: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomized strategic phase III trial (FFCD 0301). Gut 59: 1527-1534, 2010.
11. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Gorner M, Molle M, Hilbig A, Dorken B, Riess H and Oettle H: A randomized trial in patients with gemcitabine-refractory pancreatic cancer. Final results of the CONKO 003 study (abstract). J Clin Oncol 26: 215s, 2008.
12. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M and Culine S: 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 80: 301-306, 2011.
13. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC and Lee JL: A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658-1663, 2009.
14. Taïeb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G and Desrame J: FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: Results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18:498-503, 2007.
15. Saif MW: New developments in the treatment of pancreatic cancer. Highlights from the 44th ASCO Annual Meeting. Chicago, IL, USA. May 30-June 3, 2008. 9: 391-397, 2008.
16. Gebbia V, Maiello E, Giuliani F, Borsellino N, Caruso M, Di Maggio G, Ferraù F, Bordonaro R, Verderame F, Tralongo P, Di Cristina L, Agueli R, Russo P and Colucci G: Second-line chemotherapy in advanced pancreatic carcinoma: A multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 18(Suppl 6): vi124-127, 2007.